Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study

AbstractObjectiveTo estimate the effectiveness of mRNA covid-19 vaccines against symptomatic infection and severe outcomes (hospital admission or death).DesignTest negative design study.SettingOntario, Canada between 14 December 2020 and 19 April 2021.Participants324 033 community dwelling people ag...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ (Online) Ročník 374; s. n1943
Hlavní autoři: Chung, Hannah, He, Siyi, Nasreen, Sharifa, Sundaram, Maria E, Buchan, Sarah A, Wilson, Sarah E, Chen, Branson, Calzavara, Andrew, Fell, Deshayne B, Austin, Peter C, Wilson, Kumanan, Schwartz, Kevin L, Brown, Kevin A, Gubbay, Jonathan B, Basta, Nicole E, Mahmud, Salaheddin M, Righolt, Christiaan H, Svenson, Lawrence W, MacDonald, Shannon E, Janjua, Naveed Z, Tadrous, Mina, Kwong, Jeffrey C
Médium: Journal Article
Jazyk:angličtina
Vydáno: England British Medical Journal Publishing Group 20.08.2021
BMJ Publishing Group LTD
BMJ Publishing Group Ltd
Témata:
2019-nCoV Vaccine mRNA-1273
Adolescent
Adult
Aged
BNT162 Vaccine
COVID-19
COVID-19 - diagnosis
COVID-19 - mortality
COVID-19 - prevention & control
COVID-19 Nucleic Acid Testing - statistics & numerical data
COVID-19 vaccines
COVID-19 Vaccines - therapeutic use
Female
Humans
Immunization
Laboratories
Male
Middle Aged
Mutation
Ontario - epidemiology
Patient Admission - statistics & numerical data
Polymerase chain reaction
Reverse transcription
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Treatment Outcome
Vaccine efficacy
Vaccines
Young Adult
Ontario
Ontario Canada
Canada
ISSN:1756-1833, 0959-8138, 1756-1833
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:AbstractObjectiveTo estimate the effectiveness of mRNA covid-19 vaccines against symptomatic infection and severe outcomes (hospital admission or death).DesignTest negative design study.SettingOntario, Canada between 14 December 2020 and 19 April 2021.Participants324 033 community dwelling people aged ≥16 years who had symptoms of covid-19 and were tested for SARS-CoV-2.InterventionsBNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine.Main outcome measuresLaboratory confirmed SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) and hospital admissions and deaths associated with SARS-CoV-2 infection. Multivariable logistic regression was adjusted for personal and clinical characteristics associated with SARS-CoV-2 and vaccine receipt to estimate vaccine effectiveness against symptomatic infection and severe outcomes.ResultsOf 324 033 people with symptoms, 53 270 (16.4%) were positive for SARS-CoV-2 and 21 272 (6.6%) received at least one dose of vaccine. Among participants who tested positive, 2479 (4.7%) were admitted to hospital or died. Vaccine effectiveness against symptomatic infection observed ≥14 days after one dose was 60% (95% confidence interval 57% to 64%), increasing from 48% (41% to 54%) at 14-20 days after one dose to 71% (63% to 78%) at 35-41 days. Vaccine effectiveness observed ≥7 days after two doses was 91% (89% to 93%). Vaccine effectiveness against hospital admission or death observed ≥14 days after one dose was 70% (60% to 77%), increasing from 62% (44% to 75%) at 14-20 days to 91% (73% to 97%) at ≥35 days, whereas vaccine effectiveness observed ≥7 days after two doses was 98% (88% to 100%). For adults aged ≥70 years, vaccine effectiveness estimates were observed to be lower for intervals shortly after one dose but were comparable to those for younger people for all intervals after 28 days. After two doses, high vaccine effectiveness was observed against variants with the E484K mutation.ConclusionsTwo doses of mRNA covid-19 vaccines were observed to be highly effective against symptomatic infection and severe outcomes. Vaccine effectiveness of one dose was observed to be lower, particularly for older adults shortly after the first dose.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1756-1833
0959-8138
1756-1833
DOI:10.1136/bmj.n1943